Please wait while the formulary information is being retrieved.
NIVESTYM (filgrastim-aafi)
- Chemotherapy-induced neutropenia
- Neutropenia secondary to AML treatment
- Prevention of neutropenia from cancer chemotherapy
- Congenital neutropenia
- Cyclic neutropenia
- Idiopathic neutropenia
- Peripheral mobilization of hematopoietic stem cells
- Severe chronic neutropenia
300 mcg/0.5 mL subcutaneous syringe
- Dosage information is not available
480 mcg/0.8 mL subcutaneous syringe
- Dosage information is not available
300 mcg/mL injection solution
- Dosage information is not available
480 mcg/1.6 mL injection solution
- Dosage information is not available
- None
Contraindicated
- None
Severe
Moderate
- Hycamtin
- topotecan
- Aortitis
Contraindicated
- Acute respiratory distress syndrome
- Alveolar hemorrhage
- Capillary leak syndrome
- Glomerulonephritis
- Leukocytosis
- Nontraumatic splenic rupture
- Sickle cell disease
Severe
Moderate
- Cutaneous vasculitis
NIVESTYM (filgrastim-aafi)
- Chemotherapy-induced neutropenia
- Neutropenia secondary to AML treatment
- Prevention of neutropenia from cancer chemotherapy
- Congenital neutropenia
- Cyclic neutropenia
- Idiopathic neutropenia
- Peripheral mobilization of hematopoietic stem cells
- Severe chronic neutropenia
- None
- Arthralgias
- Bone pain
- Fever
- Headache disorder
- Hypesthesia
- Myalgias
- Nausea
- Pain
- Pruritus of skin
- Skin rash
- Vomiting
More Frequent
Severe
Less Severe
- Hypertension
- Injection site sequelae
- Leukocytosis
- Peritonitis
- Epistaxis
- Petechiae
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute respiratory distress syndrome
- Alveolar hemorrhage
- Anaphylaxis
- Aortitis
- Capillary leak syndrome
- Cutaneous vasculitis
- Glomerulonephritis
- Hemoptysis
- Hepatomegaly
- Nontraumatic splenic rupture
- Osteoporosis
- Pulmonary hemorrhage
- Splenomegaly
- Supraventricular arrhythmias
- Sweet's syndrome
- Thrombocytopenic disorder
Less Severe
- Alopecia
- Diarrhea
- Drug-exacerbated psoriasis
- Fatigue
- General weakness
- Hematuria
- Proteinuria
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Filgrastim
Rare reports of development of MDS and AML with underlying congenital neutropenia and chronic use. Rare postmarketing reports of decreased bone density with extended use.
- 1 Day – 18 Years
- Rare reports of development of MDS and AML with underlying congenital neutropenia and chronic use. Rare postmarketing reports of decreased bone density with extended use.
Filgrastim
- Severity Level:
2
- Additional Notes: Insufficient human data; consider maternal treatment benefit
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Filgrastim
Poor oral bioavailability
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Not known; no or inclusive data | Poor oral bioavailability |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Chemotherapy-induced neutropenia | |
| D70.1 | Agranulocytosis secondary to cancer chemotherapy |
| Congenital neutropenia | |
| D70.0 | Congenital agranulocytosis |
| Cyclic neutropenia | |
| D70.4 | Cyclic neutropenia |
| Idiopathic neutropenia | |
| D70 | Neutropenia |
| D70.8 | Other neutropenia |
| D70.9 | Neutropenia, unspecified |
| Neutropenia secondary to AML treatment | |
| D70.1 | Agranulocytosis secondary to cancer chemotherapy |
| Peripheral mobilization of hematopoietic stem cells | |
| Z52.011 | Autologous donor, stem cells |
| Severe chronic neutropenia | |
| D70.8 | Other neutropenia |
| D70.9 | Neutropenia, unspecified |
| 0-9 | A-Z |
|---|---|
| D70 | Neutropenia |
| D70.0 | Congenital agranulocytosis |
| D70.1 | Agranulocytosis secondary to cancer chemotherapy |
| D70.1 | Agranulocytosis secondary to cancer chemotherapy |
| D70.4 | Cyclic neutropenia |
| D70.8 | Other neutropenia |
| D70.8 | Other neutropenia |
| D70.9 | Neutropenia, unspecified |
| D70.9 | Neutropenia, unspecified |
| Z52.011 | Autologous donor, stem cells |
Formulary Reference Tool